

Jun Zhang

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1382752/jun-zhang-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

88
papers

58,936
citations

24
h-index

117
g-index

117
ext. papers

64,883
ext. citations

6.7
avg, IF

6.87
L-index

| # | Paper | IF | Citations |
|----|---|------|-----------|
| 88 | Mutational landscape of circulating tumor DNA identifies distinct molecular features associated with therapeutic response in patients with metastatic colorectal cancer.. <i>Therapeutic Advances in Medical Oncology</i> , 2022 , 14, 17588359211070643 | 5.4 | 0 |
| 87 | Targeting interleukin-1 β and inflammation in lung cancer.. <i>Biomarker Research</i> , 2022 , 10, 5 | 8 | 4 |
| 86 | Consensus for HER2 alterations testing in non-small-cell lung cancer.. <i>ESMO Open</i> , 2022 , 7, 100395 | 6 | 2 |
| 85 | Prospective longitudinal study of kinetics of humoral response to one, two, or three doses of SARS-CoV-2 vaccine in hematopoietic cell transplant recipients.. <i>Bone Marrow Transplantation</i> , 2022 | 4.4 | 2 |
| 84 | Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer.. <i>Redox Biology</i> , 2022 , 53, 102318 | 11.3 | 0 |
| 83 | Pten-NOLC1 fusion promotes cancers involving MET and EGFR signalings. <i>Oncogene</i> , 2021 , 40, 1064-1076. | 6.2 | 3 |
| 82 | Relating Gut Microbiome and Its Modulating Factors to Immunotherapy in Solid Tumors: A Systematic Review. <i>Frontiers in Oncology</i> , 2021 , 11, 642110 | 5.3 | 12 |
| 81 | Combination of atezolizumab and pirfenidone in second-line and beyond NSCLC: A phase I/II study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS2678-TPS2678 | 2.2 | |
| 80 | Photodynamic therapy synergizes with PD-L1 checkpoint blockade for immunotherapy of CRC by multifunctional nanoparticles. <i>Molecular Therapy</i> , 2021 , 29, 2931-2948 | 11.7 | 10 |
| 79 | Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e21024-e21024 | 2.2 | 1 |
| 78 | DRAGoM: Classification and Quantification of Noncoding RNA in Metagenomic Data. <i>Frontiers in Genetics</i> , 2021 , 12, 669495 | 4.5 | 1 |
| 77 | DCLK1 isoforms and aberrant Notch signaling in the regulation of human and murine colitis. <i>Cell Death Discovery</i> , 2021 , 7, 169 | 6.9 | 1 |
| 76 | Mutational Landscape and Evolutionary Pattern of Liver and Brain Metastasis in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 237-249 | 8.9 | 6 |
| 75 | Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy. <i>Clinical Cancer Research</i> , 2021 , 27, 1296-1304 | 12.9 | 32 |
| 74 | Characterization of evolution trajectory and immune profiling of brain metastasis in lung adenocarcinoma. <i>Npj Precision Oncology</i> , 2021 , 5, 6 | 9.8 | 3 |
| 73 | Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer. <i>BMC Cancer</i> , 2021 , 21, 808 | 4.8 | 10 |
| 72 | Tying Small Changes to Large Outcomes: The Cautious Promise in Incorporating the Microbiome into Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2021 , 22, | 6.3 | 1 |

| | | | |
|----|---|------|----|
| 71 | IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 69 | 22.4 | 3 |
| 70 | Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer. <i>Journal of Cancer</i> , 2020 , 11, 551-558 | 4.5 | 4 |
| 69 | Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China. <i>Cancer Management and Research</i> , 2020 , 12, 6977-6985 | 3.6 | 13 |
| 68 | Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion. <i>Translational Lung Cancer Research</i> , 2020 , 9, 1452-1463 | 4.4 | 2 |
| 67 | Harnessing DNA Replication Stress for Novel Cancer Therapy. <i>Genes</i> , 2020 , 11, | 4.2 | 12 |
| 66 | Effectiveness and safety of low-dose apatinib in advanced gastric cancer: A real-world study. <i>Cancer Medicine</i> , 2020 , 9, 5008-5014 | 4.8 | 9 |
| 65 | MTDH/AEG-1 downregulation using pristimerin-loaded nanoparticles inhibits Fanconi anemia proteins and increases sensitivity to platinum-based chemotherapy. <i>Gynecologic Oncology</i> , 2019 , 155, 349-358 | 4.9 | 8 |
| 64 | Metadherin enhances vulnerability of cancer cells to ferroptosis. <i>Cell Death and Disease</i> , 2019 , 10, 682 | 9.8 | 18 |
| 63 | Identification of recurrent fusion genes across multiple cancer types. <i>Scientific Reports</i> , 2019 , 9, 1074 | 4.9 | 24 |
| 62 | ROR1 Potentiates FGFR Signaling in Basal-Like Breast Cancer. <i>Cancers</i> , 2019 , 11, | 6.6 | 4 |
| 61 | Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy. <i>Molecular Cancer</i> , 2019 , 18, 85 | 42.1 | 22 |
| 60 | Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer. <i>Cancer Immunology Research</i> , 2019 , 7, 630-643 | 12.5 | 93 |
| 59 | Soil physical characteristics of a degraded tropical grassland and a reforested forest: Implications for runoff generation. <i>Geoderma</i> , 2019 , 333, 163-177 | 6.7 | 24 |
| 58 | Hypoxia Induces Drug Resistance in Colorectal Cancer through the HIF-1 α /miR-338-5p/IL-6 Feedback Loop. <i>Molecular Therapy</i> , 2019 , 27, 1810-1824 | 11.7 | 55 |
| 57 | Ophiopogon japonicus inhibits radiation-induced pulmonary inflammation in mice. <i>Annals of Translational Medicine</i> , 2019 , 7, 622 | 3.2 | 5 |
| 56 | OA04.03 A Randomized Phase 3 Study of Camrelizumab plus Chemotherapy as 1st Line Therapy for Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019 , 14, S215-S216 | 8.9 | 14 |
| 55 | Bugs in the system: bringing the human microbiome to bear in cancer immunotherapy. <i>Gut Microbes</i> , 2019 , 10, 109-112 | 8.8 | 6 |
| 54 | HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib. <i>Annals of Oncology</i> , 2019 , 30, 447-455 | 10.3 | 91 |

| | | | |
|----|--|------|------|
| 53 | Water budget and run-off response of a tropical multispecies forest and effects of typhoon disturbance. <i>Ecohydrology</i> , 2019 , 12, e2055 | 2.5 | 5 |
| 52 | Advanced stage melanoma therapies: Detailing the present and exploring the future. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 133, 99-111 | 7 | 40 |
| 51 | Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma. <i>Clinical Lung Cancer</i> , 2018 , 19, e421-e430 | 4.9 | 28 |
| 50 | Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. <i>Science</i> , 2018 , 359, 97-103 | 33.3 | 1895 |
| 49 | Early detection of lung cancer by using an autoantibody panel in Chinese population. <i>Oncolimmunology</i> , 2018 , 7, e1384108 | 7.2 | 31 |
| 48 | Runoff response and sediment yield of a landslide-affected fire-climax grassland micro-catchment (Leyte, the Philippines) before and after passage of typhoon Haiyan. <i>Journal of Hydrology</i> , 2018 , 565, 524-537 | 6 | 13 |
| 47 | Lung cancer liquid biopsy assays by qPCR using iDDS probe and Wild Terminator methods.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e21178-e21178 | 2.2 | |
| 46 | Novel Antibodies Against Glycoprotein Ib Inhibit Pulmonary Metastasis By Affecting Vwf-Gpib Interaction. <i>Blood</i> , 2018 , 132, 1133-1133 | 2.2 | |
| 45 | Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin. <i>Clinical Cancer Research</i> , 2018 , 24, 858-869 | 12.9 | 16 |
| 44 | Lobar versus sub-lobar surgery for pulmonary typical carcinoid, a population-based analysis. <i>Journal of Thoracic Disease</i> , 2018 , 10, 5850-5859 | 2.6 | 6 |
| 43 | The Serum Level of IL-1B Correlates with the Activity of Chronic Pulmonary Aspergillosis. <i>Canadian Respiratory Journal</i> , 2018 , 2018, 8740491 | 2.1 | 4 |
| 42 | Novel antibodies against GPIb Inhibit pulmonary metastasis by affecting vWF-GPIb Interaction. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 117 | 22.4 | 17 |
| 41 | Central Nervous System Pseudoprogression With Nivolumab in a Patient With Squamous Cell Lung Cancer Followed by Prolonged Response. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e183-e184 | 8.9 | 4 |
| 40 | Understanding Microbiome Effect on Immune Checkpoint Inhibition in Lung Cancer: Placing the Puzzle Pieces Together. <i>Journal of Immunotherapy</i> , 2018 , 41, 359-360 | 5 | 8 |
| 39 | Atezolizumab after Nivolumab-Induced Inflammatory Polyarthritis: Can Anti-PD-L1 Immunotherapy Be Administered after Anti-PD-1-Related Immune Toxicities?. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e102-e103 | 8.9 | 8 |
| 38 | Response to Erlotinib in a Patient with Compound EGFR L747S and Exon 19 Deletion. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e129-e130 | 8.9 | 0 |
| 37 | Immunotherapy with Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrates Enhanced Antitumor Effect Against Lung Cancer. <i>Translational Oncology</i> , 2017 , 10, 132-141 | 4.9 | 9 |
| 36 | Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases. <i>Scientific Reports</i> , 2017 , 7, 42979 | 4.9 | 18 |

| | | | |
|----|---|------|-----|
| 35 | Characterization of Liver Metastasis and Its Effect on Targeted Therapy in EGFR-mutant NSCLC: A Multicenter Study. <i>Clinical Lung Cancer</i> , 2017 , 18, 631-639.e2 | 4.9 | 19 |
| 34 | Modulation of Bax and mTOR for Cancer Therapeutics. <i>Cancer Research</i> , 2017 , 77, 3001-3012 | 10.1 | 17 |
| 33 | O and HO-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. <i>Cancer Cell</i> , 2017 , 31, 487-500.e8 | 24.3 | 193 |
| 32 | Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients. <i>Oncotarget</i> , 2017 , 8, 62648-62657 | 3.3 | 15 |
| 31 | SBRT to adrenal metastases provides high local control with minimal toxicity. <i>Advances in Radiation Oncology</i> , 2017 , 2, 581-587 | 3.3 | 23 |
| 30 | Prognostic significance of Daxx NCR (Nuclear/Cytoplasmic Ratio) in gastric cancer. <i>Cancer Medicine</i> , 2017 , 6, 2063-2075 | 4.8 | 14 |
| 29 | Endobronchial aspergilloma: A case report and literature review. <i>Experimental and Therapeutic Medicine</i> , 2017 , 14, 547-554 | 2.1 | 8 |
| 28 | Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC. <i>Theranostics</i> , 2017 , 7, 4753-4762 | 12.1 | 21 |
| 27 | FANCD2 and DNA Damage. <i>International Journal of Molecular Sciences</i> , 2017 , 18, | 6.3 | 22 |
| 26 | Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status. <i>Oncotarget</i> , 2017 , 8, 59008-59022 | 3.3 | 7 |
| 25 | Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities. <i>Acta Biochimica Et Biophysica Sinica</i> , 2016 , 48, 11-6 | 2.8 | 9 |
| 24 | Feasibility of cytological specimens for ALK fusion detection in patients with advanced NSCLC using the method of RT-PCR. <i>Lung Cancer</i> , 2016 , 94, 28-34 | 5.9 | 12 |
| 23 | NEK2 as a prognostic marker and therapeutic target in adenocarcinoma of the lung.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e23282-e23282 | 2.2 | 0 |
| 22 | Surgical management of pulmonary typical carcinoids: A population-based analysis.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8540-8540 | 2.2 | |
| 21 | Retrospective comparison between high-dose cisplatin and less-intensive weekly cisplatin/paclitaxel concurrently with radiation for locally advanced head and neck cancer (LAHNC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e17535-e17535 | 2.2 | |
| 20 | Targeting DNA Replication Stress for Cancer Therapy. <i>Genes</i> , 2016 , 7, | 4.2 | 47 |
| 19 | EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1718-28 | 8.9 | 92 |
| 18 | Tuberculosis in umbilical cord blood transplant recipients: clinical characteristics and challenges. <i>Bone Marrow Transplantation</i> , 2015 , 50, 465-8 | 4.4 | 3 |

| | | | |
|----|---|------|-------|
| 17 | Targeting HER (ERBB) signaling in head and neck cancer: An essential update. <i>Molecular Aspects of Medicine</i> , 2015 , 45, 74-86 | 16.7 | 16 |
| 16 | EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1546-52 | 8.9 | 28 |
| 15 | High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 778-783 | 8.9 | 92 |
| 14 | Targeting KRAS mutant non-small cell lung cancer (NSCLC) with deltarasin: A small molecule inhibitor of KRAS-PDE α interaction. <i>Journal of Clinical Oncology</i> , 2015 , 33, e13597-e13597 | 2.2 | 1 |
| 13 | Mutated Fanconi anemia pathway in non-Fanconi anemia cancers. <i>Oncotarget</i> , 2015 , 6, 20396-403 | 3.3 | 20 |
| 12 | LKB1 Tumor Suppressor: Therapeutic Opportunities Knock when LKB1 Is Inactivated. <i>Genes and Diseases</i> , 2014 , 1, 64-74 | 6.6 | 24 |
| 11 | HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma. <i>British Journal of Cancer</i> , 2014 , 110, 1169-78 | 8.7 | 77 |
| 10 | Phenformin combines with selumetinib in targeting KRAS mutant non-small cell lung cancer cells with alternative LKB1 status. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2589-2589 | 2.2 | |
| 9 | Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. <i>Science</i> , 2011 , 333, 1154-7 | 33.3 | 1331 |
| 8 | Novel expression of CST1 as candidate senescence marker. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2011 , 66, 723-31 | 6.4 | 5 |
| 7 | LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 18892-7 | 11.5 | 125 |
| 6 | Defined genetic events associated with the spontaneous in vitro transformation of ELA/Ras-expressing human IMR90 fibroblasts. <i>Carcinogenesis</i> , 2006 , 27, 350-9 | 4.6 | 13 |
| 5 | The candidate tumor suppressor CST6 alters the gene expression profile of human breast carcinoma cells: down-regulation of the potent mitogenic, motogenic, and angiogenic factor autotaxin. <i>Biochemical and Biophysical Research Communications</i> , 2006 , 340, 175-82 | 3.4 | 22 |
| 4 | Ethanol alters cellular activation and CD14 partitioning in lipid rafts. <i>Biochemical and Biophysical Research Communications</i> , 2005 , 332, 37-42 | 3.4 | 68 |
| 3 | Cystatin m: a novel candidate tumor suppressor gene for breast cancer. <i>Cancer Research</i> , 2004 , 64, 6957-64 | 6.1 | 74 |
| 2 | Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells. <i>Oncogene</i> , 2004 , 23, 2206-15 | 6.15 | 69 |
| 1 | Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. <i>Nucleic Acids Research</i> , 1997 , 25, 3389-402 | 20.1 | 53786 |